The FDA recommends a brain MRI before starting lecanemab or donanemab and periodic brain MRIs during treatment to monitor for brain swelling or bleeding.
Notes on verification
Confirmed via official FDA-approved prescribing information for both Leqembi and Kisunla, plus an FDA Drug Safety Communication reinforcing MRI monitoring requirements. [tier=silver indep_score=0.925 clusters=2 claim_tier=notable]
Sources
- Dementia - Diagnosis and treatment (seed:health_and_medicine)
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761248s004lbl.pdf (corroboration)
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761269s013lbl.pdf (corroboration)
- https://www.fda.gov/drugs/drug-safety-communications/fda-recommend-additional-earlier-mri-monitoring-patients-alzheimers-disease-taking-leqembi-lecanemab (corroboration)
- https://kisunla.lilly.com/hcp/dosing-monitoring (corroboration)